BPG is committed to discovery and dissemination of knowledge
Featured Articles
5/17/2019 6:59:17 AM | Browse: 141 | Download: 82
Publication Name World Journal of Meta-Analysis
Manuscript ID 47569
Country of Manuscript Source United Arab Emirates
2019-03-17 07:41
Peer-Review Started
2019-03-18 00:09
To Make the First Decision
2019-04-17 05:29
Return for Revision
2019-04-17 09:22
2019-04-21 04:34
Second Decision
2019-04-22 10:33
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2019-04-23 04:24
Articles in Press
2019-04-23 04:24
Publication Fee Transferred
Edit the Manuscript by Language Editor
2019-04-25 22:09
Typeset the Manuscript
2019-04-29 07:01
Publish the Manuscript Online
2019-04-30 03:02
ISSN 2308-3840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Specialty Medicine, Research and Experimental
Manuscript type Minireviews
Article Title Drug interactions of dipeptidyl peptidase 4 inhibitors involving CYP enzymes and P-gp efflux pump
Manuscript Source Unsolicited Manuscript
All Author List Naina Mohamed Pakkir Maideen
Funding Agency and Grant Number
Correspondence To Naina Mohamed Pakkir Maideen, PhD, Doctor, Pharmacist, Pharmacologist, Department of Pharmacy, Dubai Health Authority, Al Maktoum Bridge Street, Dubai 4545, United Arab Emirates. nmmaideen@dha.gov.ae
Keywords Drug interactions; Sitagliptin; Saxagliptin; Linagliptin; Gemigliptin; Teneligliptin; Vildagliptin; Anagliptin; CYP3A4; P-gp efflux pump
Core Tip The probability of adverse drug interactions is higher among Diabetic patients due to the concomitant administration of antidiabetic drugs with multiple medications to treat comorbidities such as hypertension, dyslipidemia, other cardiovascular problems, infections, depression, and others. Dipeptidyl peptidase 4 (DPP4) inhibitors are oral antidiabetic drugs approved to manage type 2 diabetes mellitus. Some of the DPP4 inhibitors have been identified as the substrates of CYP3A4/5 enzymes and P-gp efflux pump. The drugs inhibiting or inducing CYP3A4/5 enzymes and/or P-gp can alter the pharmacokinetics of DPP4 inhibitors. The prescribers and the pharmacists are required to be aware of the drugs altering the pharmacokinetics of DPP4 inhibitors significantly, to prevent adverse drug interactions.
Publish Date 2019-04-30 03:02
Citation Maideen NMP. Drug interactions of dipeptidyl peptidase 4 inhibitors involving CYP enzymes and P-gp efflux pump. World J Meta-Anal 2019; 7(4): 156-161
Url https://www.wjgnet.com/2308-3840/full/v7/i4/156.htm
DOI https://dx.doi.org/10.13105/wjma.v7.i4.156
Full Article (PDF) WJMA-7-156.pdf
Full Article (Word) WJMA-7-156.docx
Manuscript File FP6834_de16_CE1MS_edit2.docx
Answering Reviewers 47569-Answering reviewers.pdf
Audio Core Tip 47569-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 47569-Conflict-of-interest statement.pdf
Copyright License Agreement 47569-Copyright license agreement.pdf
Peer-review Report 47569-Peer-review(s).pdf
Scientific Misconduct Check 47569-Scientific misconduct check.pdf
Scientific Editor Work List 47569-Scientific editor work list.pdf